Physician

Annie Hyon, D.O

According to 2025 Medicare claims, Annie Hyon, D.O (NPI: 1508007451) practices nephrology in the Yuma, AZ market, with the plurality of this provider's patient population coming from Yuma, AZ. This provider's primary affiliated billing organization is YUMA NEPHROLOGY PC (NPI: 1235185729; TIN: 860820509) and primary practice location at 85364-9998.

Hyon's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 737 traditional Medicare patients, billed 18,386 HCPCS/CPT codes, and received $280,712 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,336 prescription claims across 615 beneficiaries totaling $710,054 in drug costs, led by Velphoro (Sucroferric Oxyhydroxide). DME data shows 362 claims. Open Payments data shows 8 records totaling $118. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a higher plateau to a lower plateau, from $743,649 to $710,054. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	797	17,652	$385,021
2016	856	20,581	$382,989
2017	846	37,974	$392,618
2018	831	45,726	$362,196
2019	1,165	56,559	$527,505
2020	917	29,989	$443,180
2021	744	23,262	$303,584
2022	684	11,049	$270,545
2023	670	9,629	$240,964
2024	737	18,386	$280,712

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	447	3,828	$743,649
2016	514	5,050	$1,011,655
2017	548	5,308	$1,141,124
2018	514	4,081	$402,311
2019	509	3,260	$341,115
2020	478	2,934	$430,671
2021	456	2,706	$384,197
2022	467	2,701	$422,747
2023	522	2,940	$637,058
2024	615	3,336	$710,054

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	24	$605
2017	N/R	123	$6,029
2018	N/R	165	$7,439
2019	11	195	$7,363
2020	N/R	242	$8,357
2021	11	270	$8,552
2022	12	291	$7,382
2023	23	394	$6,988
2024	11	362	$6,155

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	254	349	$69
80069	Kidney function blood test panel	243	376	$9
36415	Insertion of needle into vein for collection of blood sample	292	644	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	252	482	$8
83735	Magnesium level	247	384	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Velphoro	Sucroferric Oxyhydroxide	43	1,762	$147,860
Lokelma	Sodium Zirconium Cyclosilicate	149	7,132	$137,861
Farxiga	Dapagliflozin Propanediol	84	4,884	$83,144
Jardiance	Empagliflozin	35	3,030	$53,145
Ozempic	Semaglutide	15	1,066	$32,620

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	80	$1,831
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	11	89	$1,581
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	71	$1,435
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	99	$1,292
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	N	N/R	23	$16

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	8	$118	OPKO Pharmaceuticals, LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Annie Hyon, D.O?

Tedicare shows public-source Medicare data for Annie Hyon, D.O (NPI 1508007451), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Annie Hyon, D.O have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Annie Hyon, D.O?

Annie Hyon, D.O is linked to YUMA NEPHROLOGY PC (billing NPI 1235185729) in the available physician profile data.

Does Annie Hyon, D.O have Open Payments data?

Annie Hyon, D.O has 8 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.